ZIM
ECYT

Zacks Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Zacks Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-96,607
Closed -$136K – 687
2017
Q3 		$136K Buy
+96,607
New +$135K ﹤0.01% 559
2014
Q2 		– Sell
-15,501
Closed -$369K – 804
2014
Q1 		$369K Buy
+15,501
New +$225K 0.01% 495

Other funds holding ECYT

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zacks Investment Management's ECYT Position: Q4 2017 in Review

Zacks Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 96,607 shares — an estimated $136K sold.

Zacks Investment Management first reported a position in ECYT in Q1 2014 and held it in 2 quarters. The position peaked at $369K in Q1 2014. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

  • Zacks Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Zacks Investment Management sold 96,607 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $136K.
  • Zacks Investment Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • Zacks Investment Management's Endocyte, Inc. Common Stock position peaked at $369K in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Zacks Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.